As of January 22, 2025, Beam Therapeutics (BEAM) has a market cap of $2.00 billion USD. According to our data, Beam Therapeutics is ranked No.4135 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $2.00 B |
-2.54%
|
Dec 31, 2024 | $2.05 B |
-8.89%
|
Dec 29, 2023 | $2.25 B |
-30.40%
|
Dec 30, 2022 | $3.24 B |
-50.92%
|
Dec 31, 2021 | $6.60 B |
-2.39%
|
Dec 31, 2020 | $6.76 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Editas Medicine
EDIT
|
$0.10 B |
-0.000 M
|
USA
|
CRISPR Therapeutics
CRSP
|
$3.82 B |
6.828 M
|
Switzerland
|
Intellia Therapeutics
NTLA
|
$1.03 B |
0.000 M
|
USA
|
Sangamo Therapeutics
SGMO
|
$0.23 B |
-0.000 M
|
USA
|
bluebird bio
BLUE
|
$77.02 M |
0.000 M
|
USA
|
REGENXBIO
RGNX
|
$0.37 B |
0.000 M
|
USA
|
Precision BioSciences
DTIL
|
$36.21 M |
-0.000 M
|
USA
|
Allogene Therapeutics
ALLO
|
$0.40 B |
0.000 M
|
USA
|
Sana Biotechnology
SANA
|
$0.78 B |
-0.000 M
|
USA
|
Verve Therapeutics
VERV
|
$0.59 B |
-0.000 M
|
USA
|
Cellectis
CLLS
|
$0.16 B |
4.583 M
|
France
|
Poseida Therapeutics
PSTX
|
$0.93 B |
0.000 M
|
USA
|
Market Cap | = | BEAM Stock Price | * | BEAM Shares Outstanding |
= | $24.17 | * | 82.81 M | |
= | $2.00 B |